"First-listed Chinese Noodle Restaurant" Xiao Noodles Announces 2025 Annual Results

Achieving Dual Success in Scale and Profitability, with a Substantial Increase in Annual Profit

Performance Highlights:

• Revenue: RMB1,622.4 million, representing a year-on-year increase of 40.5%
• Net Profit: RMB106.1 million, representing a year-on-year increase of 74.8%
• Adjusted Net Profit (a non-IFRS measure): RMB135.4 million, representing a year-on-year increase of 111.9%
• In 2025, the Group opened 156 new restaurants, comprising 134 self-operated restaurants and 22 franchised restaurants
• As of December 31, 2025, the Group operated 395 self-operated restaurants and 92 franchised restaurants across 24 cities in Mainland China, 15 restaurants in the Hong Kong Special Administrative Region and 1 restaurant in Singapore

HONG KONG, March 30, 2026 /PRNewswire/ -- Guangzhou Xiao Noodles Catering Management Co., Ltd. (the "Company" or "Xiao Noodles"; Stock Code: 2408.HK) is pleased to announce that the board of directors of the Company announces the unaudited consolidated results of the Company and its subsidiaries (the "Group") for the year ended 31 December 2025 (the "Reporting Period").

As the "First-listed Chinese Noodle Restaurant" on the Hong Kong Stock Exchange, the Group leveraged its standardized operational system and core product strengths in 2025 to comprehensively drive store expansion and optimize its business portfolio. Through synergies across its business segments, the Group achieved significant revenue growth during a period of profound industry restructuring.

During the Reporting Period, the Group generated revenue of RMB1,622.4 million, representing a year-on-year increase of 40.5%; net profit reached RMB106.1 million, up 74.8% year-on-year; and adjusted net profit (a non-IFRS measure) amounted to RMB135.4 million, up 111.9% year-on-year. In 2025, the Group opened 156 new restaurants, including 134 self-operated restaurants and 22 franchised restaurants. As of December 31, 2025, the Group operated a total of 503 restaurants, comprising 395 self-operated and 92 franchised restaurants across 24 cities in mainland China, 15 restaurants in the Hong Kong Special Administrative Region, and one restaurant in Singapore, marking significant expansion achievements.

Steady Growth in Self-operated Restaurants, Reinforcing the Core Business

The Group's revenue primarily comes from self-operated restaurants operation and franchised restaurants management. Self-operated restaurants serve as the core revenue pillar, while franchised restaurants emerged as a new growth engine. The synergistic efforts of these two business segments are driving the Group's continued improvement in profitability.

In terms of self-operated restaurant business, in 2025, the operational quality and efficiency of self-operated restaurants continued to improve, with core operational indicators delivering outstanding performance. The Group's revenue from self-operated restaurant operations increased from RMB1,001.0 million in 2024 by 44.9% to RMB1,450.2 million in 2025, primarily attributable to the increase in the number of self-operated restaurants. Revenue from self-operated restaurant operations as a percentage of total revenue increased from 86.7% in 2024 to 89.4% in 2025. In addition, revenue from delivery business as a percentage of total revenue increased rapidly from 15.6% for the year ended December 31, 2024 to 23.3% for the year ended December 31, 2025.

During the Reporting Period, the average spending per order at the Group's self-operated restaurants amounted to RMB29.9, remaining stable, while average daily orders per restaurant increased from 386 orders in 2024 to 406 orders in 2025, demonstrating improved customer attraction.

In terms of same-store operating performance, it remained robust, with same-store sales amounting to RMB745.612 million, representing a year-on-year increase of 1.0%; average daily orders per same store increased from 391 orders in 2024 to 427 orders in 2025, and the average spending per order at same stores was RMB29.4, remaining stable.

In terms of franchised restaurants, in 2025, the Group's franchised restaurant operations delivered excellent performance, with improvements across various core indicators. The Group's revenue from franchise management increased from RMB152.5 million in 2024 by 12.3% to RMB171.3 million in 2025, primarily attributable to the increase in the number of restaurants.

Steady Progress in Domestic and Overseas Expansion to Actively Explore New Growth Opportunities

While maintaining the steady development of its existing business, the Group has actively expanded its business to the Hong Kong Special Administrative Region and overseas markets, steadily increasing market penetration and seeking new growth opportunities.

As of December 31, 2025, the Group had successfully opened 15 restaurants in the Hong Kong Special Administrative Region and one restaurant in Singapore, marking initial achievements in its overseas market layout. During the Reporting Period, the Hong Kong market delivered an outstanding overall operating performance with remarkable results in regional expansion. Going forward, the Group plans to further expand into Southeast Asia to enhance its brand recognition, optimize its market layout, and drive long-term, steady and diversified revenue growth.

Future Outlook

Looking ahead to 2026, driven by a series of national policies to stabilize the economy and promote growth, China's domestic economy and consumer market are expected to continue their recovery, with residents' consumption capacity and confidence further strengthened, injecting strong impetus into the development of the Chinese fast food industry.

Against this backdrop, the Group will firmly seize market opportunities, leverage its brand advantage as the "First-listed Chinese Noodle Restaurant", and promote the expansion of its restaurant network, with plans to open 150 to 180 new restaurants in 2026. Meanwhile, the Group will continue to increase investment in brand building to deepen brand recognition and influence, steadily advance its overseas market expansion, consolidate its leading position in the Chinese noodle restaurant segment, and strive to create greater value for shareholders.

About Guangzhou Xiao Noodles Catering Management Co., Ltd.

Guangzhou Xiao Noodles Catering Management Co., Ltd. is a Chinese noodle restaurants operator in China. We operate the Xiao Noodles (遇見小麵) brand in the Chinese Mainland and Hong Kong SAR. Our restaurant network encompassed 395 self-operated restaurants and 92 franchised restaurants across 24 cities in the Chinese Mainland and 15 restaurants in Hong Kong SAR and one restaurant in Singapore as of December 31, 2025. According to Frost & Sullivan, the Company ranked fourth largest Chinese noodle restaurants operator in China in terms of GMV in 2024. Based on the same source, we ranked the thirteenth in the overall Chinese QSR market in terms of GMV in 2024.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

"First-listed Chinese Noodle Restaurant" Xiao Noodles Announces 2025 Annual Results

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". These achievements mark WuXi Biologics' ninth consecutive year winning the CDMO Leadership Awards, underscoring its commitment to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are honored to receive the CDMO Leadership Award for the ninth consecutive year. This recognition reflects the continued trust of our global partners and the dedication of our more than 13,000 employees worldwide. By advancing integrated technology platforms, manufacturing excellence, and digital innovation, we remain committed to helping our partners accelerate development, ensure quality and scalability, and bring life‑saving biologics to patients worldwide."

As of the end of 2025, WuXi Biologics has 945 integrated projects on its platform, making it one of the world's largest portfolios of complex biologics. Among them, more than 50% are complex modalities, such as bi-/multi-specific antibodies and ADCs. Supported by innovative technology platforms, deep accumulated know‑how in molecule and process development, and a leading global quality system, WuXi Biologics' timelines from DNA to IND and from IND to BLA have been shortened to 6 months and 15 months, respectively, compared with industry averages of 10–12 months and 24–36 months. From technology transfer to PPQ, the standard timeline is 6 months, with an accelerated timeline of 3.5 months —compared with industry timelines of over 12 months.

WuXi Biologics has developed a holistic strategy to deliver scalable and agile manufacturing solutions that help global clients address evolving market demand. These include the application of large‑volume single‑use bioreactors (SUBs) ranging from 2,000 L and 4,000 L to 5,000 L; the combination of multiple SUBs to enable large‑scale manufacturing of up to 16,000 L; the implementation of innovative intensified bioprocessing such as WuXiUP™ (continuous bioprocessing platform) and WuXiUI™ (ultra-intensified fed-batch bioprocessing platform) to significantly enhance productivity; and the application of WuXia™ TrueSite, a next‑generation targeted integration (TI)-based CHO cell line platform. WuXia™ TrueSite achieves average mAb titers exceeding 8.0 g/L with outstanding expression stability across 60 generations.

Building on its innovative technology platforms, WuXi Biologics consistently leads the industry in manufacturing and bioprocessing excellence. The company has achieved a 100% success rate in PPQ campaigns. It has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners since 2017. The strong manufacturing track record is underpinned by WuXi Biologics' rigorous, global quality system. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of global clients' trust.

WuXi Biologics is also pioneering digital innovation to transform biologics research, development and manufacturing. It has integrated digital innovation across end-to-end R&D, manufacturing, operations, and customer engagement, driving faster timelines, superior quality, and full partnership transparency. By leveraging digital manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain, consistent data integrity and high product quality, while its advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLab^™ to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing.

The CDMO Leadership Awards and ceremony are produced by Life Science Connect and hosted by Outsourced Pharma. The awards have partnered with the Tufts Center for the Study of Drug Development (Tufts CSDD) to independently design, field, and analyze the research underlying the 2026 awards program.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 13,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts 

Media 
PR@wuxibiologics.com

Business
info@wuxibiologics.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year